NovaBridge Biosciences (NBP)
NASDAQ: NBP · Real-Time Price · USD
3.505
+0.005 (0.14%)
At close: Mar 9, 2026, 4:00 PM EDT
3.470
-0.035 (-1.00%)
After-hours: Mar 9, 2026, 6:05 PM EDT
NovaBridge Biosciences Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
32
Market Cap
404.10M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Niagen Bioscience | 129.42M |
| Sutro Biopharma | 105.65M |
| Enanta Pharmaceuticals | 66.98M |
| Autolus Therapeutics | 51.13M |
| Crescent Biopharma | 10.84M |
| PureTech Health | 6.39M |
| Immutep | 5.28M |
| Upstream Bio | 2.80M |
NBP News
- 3 hours ago - NovaBridge Biosciences (NBP) Discusses Phase 2a Clinical Data and Development Plan for VIS-101 in Wet Age-Related Macular Degeneration Transcript - Seeking Alpha
- 8 hours ago - Mid-Cap NovaBridge Biosciences Stock Jumps Fueled By Positive Study Data In Eye Disease - Benzinga
- 11 hours ago - NovaBridge and Visara Announce Positive Results from VIS-101 Phase 2a Wet AMD Study - GlobeNewsWire
- 6 days ago - NovaBridge to Host Business Update Call to Review Phase 2a Data for VIS-101 in Wet AMD on Monday, March 9, 2026 - GlobeNewsWire
- 7 days ago - NovaBridge to Present at the Leerink Partners 2026 Global Healthcare Conference - GlobeNewsWire
- 18 days ago - NovaBridge Appoints Biotech Leader, Emmett T. Cunningham, Jr, MD, PhD, MPH, as Vice Chairman of the Board to Further Accelerate Global Biotech Platform - GlobeNewsWire
- 20 days ago - NovaBridge Doses First Patient in Global, Randomized Phase 2 Study of Givastomig Combined with Immunochemotherapy in Patients with 1L Metastatic Gastric Cancer - GlobeNewsWire
- 6 weeks ago - NovaBridge Announces Open Market Purchases by Executive Chairman, Fu Wei - GlobeNewsWire